Solution for injection Ficocyte (1 prefilled syringe/box)

Indications

- FICOCYTE is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.
- The safety and efficacy of FICOCYTE are similar in adults and children receiving cytotoxic chemotherapy.
- FICOCYTE is indicated for the mobilisation of peripheral blood progenitor cells (PBPC).
- In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an ANC of 0.5 x 109/L, and a history of severe or recurrent infections, long term administration of FICOCYTE is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
FICOCYTE is indicated for the treatment of persistent neutropenia (Absolute neutrophil count (ANC) less than or equal to 1.0 x109/L) in patients with advanced HIV infection inappropriate.

Contraindications

- Hypersensitivity to the active substance or to any of the excipients. FICOCYTE should not be used to increase the dose of cytotoxic chemotherapy beyond established dosage regimens.
- With severe congenital neutropenia (Kostman's syndrome) with abnormal cytogenetics.

Compositon/Ingredients

Storage

Store at temperature below 30°C, protect from light.